Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, has announced its financial results for the first quarter of 2025, alongside updates on its clinical programs. The company is focused on developing treatments for rare diseases with significant unmet medical needs, with several key milestones anticipated in the near future.
Christopher J. Schaber, PhD, CEO and president of Soligenix, emphasized the company's strategic focus on advancing its clinical programs. Notably, top-line results from a phase 3 confirmatory study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL) are expected in 2026. Additionally, phase 2 studies of SGX945 in Behçet’s disease and SGX302 in mild-to-moderate psoriasis are set to report top-line results in the second half of 2025.
These developments are crucial for patients suffering from rare diseases who have limited treatment options. The advancement of Soligenix's pipeline not only represents potential new therapies for these conditions but also underscores the importance of continued investment and research in the biopharmaceutical sector to address complex medical challenges.
